PDCD1 and neoplasm: In particular, two landmark studies showed that anti-PD-1 treatment failed to reinvigorate CD8+ T cell tumor surveillance but paradoxically activated Cxcr6+ auto-aggressive CD8+TNF+PD-1+ T cells, which induce liver damage, cirrhosis, and HCC.3